These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 20174973)

  • 1. Primary care physicians' attitudes regarding race-based therapies.
    Frank D; Gallagher TH; Sellers SL; Cooper LA; Price EG; Odunlami AO; Bonham VL
    J Gen Intern Med; 2010 May; 25(5):384-9. PubMed ID: 20174973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BiDil for heart failure in black patients: The U.S. Food and Drug Administration perspective.
    Temple R; Stockbridge NL
    Ann Intern Med; 2007 Jan; 146(1):57-62. PubMed ID: 17200223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Flaws in the U.S. Food and Drug Administration's rationale for supporting the development and approval of BiDil as a treatment for heart failure only in black patients.
    Ellison GT; Kaufman JS; Head RF; Martin PA; Kahn JD
    J Law Med Ethics; 2008; 36(3):449-57. PubMed ID: 18840235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gray area for new heart failure drug. Although the FDA approved BiDil for blacks with heart failure, it may work in anyone.
    Harv Heart Lett; 2005 Nov; 16(3):1-2. PubMed ID: 16363036
    [No Abstract]   [Full Text] [Related]  

  • 5. Influence of patient race on physician prescribing decisions: a randomized on-line experiment.
    Rathore SS; Ketcham JD; Alexander GC; Epstein AJ
    J Gen Intern Med; 2009 Nov; 24(11):1183-91. PubMed ID: 19705205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of hydralazine/isosorbide dinitrate in racial/ethnic subgroups with heart failure.
    Hammermeister KE; Fairclough D; Emsermann CB; Hamman R; Ho M; Phibbs S; Plomondon M; Valuck R; West D; Steiner JF
    Clin Ther; 2009 Mar; 31(3):632-43. PubMed ID: 19393854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BiDil for heart failure in black patients: implications of the U.S. Food and Drug Administration approval.
    Bibbins-Domingo K; Fernandez A
    Ann Intern Med; 2007 Jan; 146(1):52-6. PubMed ID: 17200222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BiDil: assessing a race-based pharmaceutical.
    Brody H; Hunt LM
    Ann Fam Med; 2006; 4(6):556-60. PubMed ID: 17148635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. "Special treatment": BiDil, Tuskegee, and the logic of race.
    Reverby SM
    J Law Med Ethics; 2008; 36(3):478-84. PubMed ID: 18840239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The paradox of race in the Bidil debate.
    Crawley L
    J Natl Med Assoc; 2007 Jul; 99(7):821-2. PubMed ID: 17668653
    [No Abstract]   [Full Text] [Related]  

  • 11. Bidil: recontextualizing the race debate.
    Séguin B; Hardy B; Singer PA; Daar AS
    Pharmacogenomics J; 2008 Jun; 8(3):169-73. PubMed ID: 18195727
    [No Abstract]   [Full Text] [Related]  

  • 12. Physicians' attitudes toward race, genetics, and clinical medicine.
    Bonham VL; Sellers SL; Gallagher TH; Frank D; Odunlami AO; Price EG; Cooper LA
    Genet Med; 2009 Apr; 11(4):279-86. PubMed ID: 19265721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prescribing BiDil: is it black and white?
    Haga SB; Ginsburg GS
    J Am Coll Cardiol; 2006 Jul; 48(1):12-4. PubMed ID: 16814642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Introduction: Facts and fictions: BiDil and the resurgence of racial medicine.
    Dorr GM; Jones DS
    J Law Med Ethics; 2008; 36(3):443-8. PubMed ID: 18840234
    [No Abstract]   [Full Text] [Related]  

  • 15. The effect of cognitive load and patient race on physicians' decisions to prescribe opioids for chronic low back pain: a randomized trial.
    Burgess DJ; Phelan S; Workman M; Hagel E; Nelson DB; Fu SS; Widome R; van Ryn M
    Pain Med; 2014 Jun; 15(6):965-74. PubMed ID: 24506332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of ACE inhibitors or beta-blockers in patients treated with the fixed-dose combination of isosorbide dinitrate/hydralazine in the African-American Heart Failure Trial.
    Ghali JK; Tam SW; Ferdinand KC; Lindenfeld J; Sabolinski ML; Taylor AL; Worcel M; Curry CL; Cohn JN;
    Am J Cardiovasc Drugs; 2007; 7(5):373-80. PubMed ID: 18041162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BiDil: primary care physicians first and cardiologist when?
    Matthews GE
    J Natl Med Assoc; 2007 Jun; 99(6):697-9; quiz 700. PubMed ID: 17595944
    [No Abstract]   [Full Text] [Related]  

  • 18. BiDil for heart failure in black patients.
    Kahn JD
    Ann Intern Med; 2007 Aug; 147(3):215; author reply 215-6. PubMed ID: 17679713
    [No Abstract]   [Full Text] [Related]  

  • 19. BiDil for heart failure in black patients.
    Bibbins-Domingo K; Fernandez A
    Ann Intern Med; 2007 Aug; 147(3):214-5; author reply 215-6. PubMed ID: 17679712
    [No Abstract]   [Full Text] [Related]  

  • 20. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure.
    Taylor AL; Ziesche S; Yancy C; Carson P; D'Agostino R; Ferdinand K; Taylor M; Adams K; Sabolinski M; Worcel M; Cohn JN;
    N Engl J Med; 2004 Nov; 351(20):2049-57. PubMed ID: 15533851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.